- Home
- PLUR vs SABS Comparison
PLUR vs SABS Comparison
Compare PLUR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- SABS
- Stock Information
- Founded
- PLUR 2001
- SABS 2014
- Country
- PLUR Israel
- SABS United States
- Employees
- PLUR N/A
- SABS N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- SABS Health Care
- Exchange
- PLUR Nasdaq
- SABS Nasdaq
- Market Cap
- PLUR 36.9M
- SABS 31.2M
- IPO Year
- PLUR N/A
- SABS N/A
- Fundamental
- Price
- PLUR $3.91
- SABS $3.01
- Analyst Decision
- PLUR Strong Buy
- SABS Strong Buy
- Analyst Count
- PLUR 1
- SABS 3
- Target Price
- PLUR $12.00
- SABS $9.00
- AVG Volume (30 Days)
- PLUR 10.5K
- SABS 452.5K
- Earning Date
- PLUR 11-11-2025
- SABS 11-06-2025
- Dividend Yield
- PLUR N/A
- SABS N/A
- EPS Growth
- PLUR N/A
- SABS N/A
- EPS
- PLUR N/A
- SABS N/A
- Revenue
- PLUR $1,336,000.00
- SABS $114,698.00
- Revenue This Year
- PLUR $97.38
- SABS N/A
- Revenue Next Year
- PLUR $293.97
- SABS N/A
- P/E Ratio
- PLUR N/A
- SABS N/A
- Revenue Growth
- PLUR 309.82
- SABS N/A
- 52 Week Low
- PLUR $3.33
- SABS $1.00
- 52 Week High
- PLUR $7.13
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- PLUR 41.69
- SABS 66.44
- Support Level
- PLUR $3.60
- SABS $2.90
- Resistance Level
- PLUR $4.09
- SABS $3.19
- Average True Range (ATR)
- PLUR 0.18
- SABS 0.21
- MACD
- PLUR -0.02
- SABS 0.05
- Stochastic Oscillator
- PLUR 30.69
- SABS 88.07
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.